SCHEMBL5110062

SCHEMBL5110062

Fc1ccccc1-c1cncc(N2CCN3CCC2C3)c1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 7/20 0.40
CHRNB4 P30926 3/20 0.40
CHRNA3 P32297 3/20 0.40
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
CHRNA7 P36544 1/20 0.40
CHRNA1 P02708 1/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
HTR3A P46098 1/20 0.40
KCNH2 Q12809 2/20 0.39
MAPT P10636 1/20 0.35
GSK3B P49841 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5112800 0.99 PIM1 (0.39) PIM1CHRNB4CHRNA3CYP11B1CYP11B2
SCHEMBL5116744 0.93 PIM1 (0.42) PIM1CHRNB4CHRNA3CYP11B1CYP11B2
SCHEMBL5116116 0.91 CYP11B1 (0.42) PIM1CHRNB4CHRNA3CYP11B1CYP11B2
SCHEMBL5121830 0.88 CHRNA1 (0.43) PIM1CHRNB4CHRNA3CYP11B1CYP11B2
SCHEMBL5111263 0.87 CHRNB4 (0.43) CHRNB4CHRNA3CHRNA7CHRNA1CHRNB2
SCHEMBL5116020 0.86 NR3C1 (0.36) CYP11B1CYP11B2KCNH2
Hydrochloric Acid SCHEMBL5122378 0.86 CHRNB4 (0.42) CHRNB4CHRNA3CHRNA7CHRNA1CHRNB2
SCHEMBL5120729 0.85 PIM1 (0.41) PIM1CHRNB4CHRNA3CYP11B1CYP11B2
Hydrochloric Acid SCHEMBL5111534 0.85 NR3C1 (0.36) CHRNA7KCNH2
SCHEMBL5108587 0.85 CYP11B1 (0.43) CHRNB4CHRNA3CYP11B1CYP11B2CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442694-B2 Diazabicyclic compounds useful in the treatment of CNS and other disorders PFIZER INC (US) 2008-10-28 US claimed
EP-1551843-A1 DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP claimed
US-20040106603-A1 Diazabicyclic compounds useful in the treatment of CNS and other disorders PFIZER INC 2004-06-03 US claimed
WO-2004024729-A1 DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS PFIZER PRODUCTS INC. (US) 2004-03-25 WO claimed
US-7442694-B2 Diazabicyclic compounds useful in the treatment of CNS and other disorders PFIZER INC (US) 2008-10-28 US disclosed
EP-1551843-A1 DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP disclosed
US-20040106603-A1 Diazabicyclic compounds useful in the treatment of CNS and other disorders PFIZER INC 2004-06-03 US disclosed
WO-2004024729-A1 DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS PFIZER PRODUCTS INC. (US) 2004-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106603-A1 Diazabicyclic compounds useful in the treatment of CNS and other disorders DBH, CHRNA6, DDT PIM1 3802/4885CHRNB4 11/4885CHRNA3 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.